Sign in

You're signed outSign in or to get full access.

Karen May

Director at Solventum
Board

About Karen May

Karen J. May, age 66, is an independent director of Solventum and serves as Chair of the Talent Committee; she joined Solventum’s board effective April 1, 2024 following the company’s spin-off from 3M . Her background spans executive leadership in human capital and finance, including CHRO roles at Mondelēz/Kraft and Baxter, and early-career auditing at PwC (CPA), with board experience in healthcare and consumer sectors . She is designated independent under Solventum’s Director Independence Guidelines (all directors other than the CEO are independent) .

Past Roles

OrganizationRoleTenureCommittees/Impact
Mondelēz International (formerly Kraft Foods)Executive Vice President & Chief Human Resources Officer2005–2018Led restructuring and dispositions; drove growth and price management .
Baxter InternationalCorporate VP & CHRO; VP HR; various VP roles1990–2005Spin-offs, M&A, and restructuring experience; global operations exposure .
PricewaterhouseCoopersCertified Public Accountant1980–1990Financial reporting and audit foundation .

External Roles

OrganizationRoleTenureCommittees/Impact
Alcon, Inc.DirectorCurrentPublic healthcare board experience; human capital and finance oversight .
MB Financial, Inc.DirectorPriorPrior public company board service .
Ace Hardware CorporationDirectorCurrentGovernance and strategic oversight in retail cooperative .

Board Governance

  • Committee assignments: Chair, Talent Committee; members include Carlos Albán, Carrie S. Cox, Darryl L. Wilson, and Shirley Edwards; 5 meetings held in 2024 .
  • Independence: All board committees are 100% independent; Talent Committee members qualify as “non-employee directors” under Rule 16b-3 .
  • Attendance: Board held 7 meetings and committees held 18 in 2024; all directors attended at least 75% of meetings for boards/committees served .
  • Leadership: Independent Chair (Carrie S. Cox); committee chairs selected based on professional experience; board is phasing out classified structure by 2028 .
  • Executive sessions: Independent directors meet regularly without management; Chair presides .
  • Shareholder votes (signal): Annual meeting (Apr 30, 2025) — Say-on-Pay approved (117.4M For; 19.25M Against; 0.87M Abstain); Board class nominees elected by majority; annual Say-on-Pay frequency favored .

Fixed Compensation

YearCash Retainer ($)Committee Chair Fee ($)Total Cash ($)Stock Awards ($)Total ($)
2024105,000350,000455,000
NotesBase board retainer policy: $120,000; Talent Committee Chair fee: $20,000; amounts prorated based on April 1, 2024 appointmentAnnual RSU ($225k) plus one-time “Founder’s grant” RSU ($125k); annual RSUs 1-year vest; Founder’s grant 2-year cliff vest

Performance Compensation

  • Director equity design: Non-employee directors receive time-vesting RSUs; no performance share units or options disclosed for directors in 2024; vesting schedules noted above .
  • Talent Committee oversight (as Chair): May oversees executive incentive design and risk assessment; 2024 AIP metrics and PSUs established and adjusted with shareholder feedback; 2025 PSUs add relative TSR as a metric .

Executive Incentive Metrics (under Talent Committee oversight)

MetricWeightThresholdTargetMaximumActual2024 Payout
AIP: Constant Currency Revenue ($M)60%7,5428,1988,8548,296115.0%
AIP: Adjusted Operating Income ($M)40%1,5331,8042,0751,812103.0%
Business Performance Factor110.2%
PSU Metric (2024–2026)WeightThreshold VestingTarget VestingMaximum Vesting
Constant Currency Revenue (3-year cumulative)60%50%100%200%
Adjusted EPS (3-year cumulative)40%50%100%200%
  • Program evolution: 2025 PSUs will preset 3-year cumulative goals and add relative TSR to align vesting with shareholder value creation .

Other Directorships & Interlocks

CompanyMarket Relation to SolventumRole/CommitteePotential Interlock/Conflict
AlconOphthalmic devices (adjacent to MedTech)DirectorNo related-party transactions disclosed; Governance Committee oversees related party reviews .
Ace HardwareRetail cooperativeDirectorNo related-party transactions disclosed .
  • Committee interlocks: No compensation committee interlocks or insider participation identified for Talent Committee members in 2024 .
  • Directorship limits: Solventum limits to ≤4 public boards for non-CEO directors; May’s current public company roles are within limits .

Expertise & Qualifications

  • Human capital leadership (CHRO roles), finance/accounting exposure (PwC); extensive spin-off/M&A and restructuring experience across global companies .
  • Skills aligned to board needs: governance, HR, audit/tax best practices for a new standalone global organization .

Equity Ownership

HolderShares Beneficially Owned% of OutstandingUnvested Director RSUsPledging/Hedging
Karen J. May<1%5,544Prohibited by Insider Trading Policy (no hedging, shorting, margin, or pledging)
  • Director stock ownership guideline: 5x annual board retainer; 5-year window to reach guideline; unvested time-based RSUs count toward guideline .
  • Compliance status: Individual compliance not disclosed; initial phase following 2024 spin-off .

Governance Assessment

  • Board effectiveness: Independent leadership, strong committee structure, active ERM, cybersecurity oversight, and frequent executive sessions support robust governance .
  • Engagement & attendance: All directors met attendance expectations (≥75%); Talent Committee met 5 times, indicating active oversight under May’s chairship .
  • Pay alignment signals: Shareholders approved Say-on-Pay; Talent Committee added relative TSR to PSUs and strengthened ownership/clawback policies, reflecting responsiveness to investor feedback .
  • Conflicts & red flags: No related-party transactions involving May disclosed; strict anti-pledging/hedging policies; no tax gross-ups for change-in-control; no single-trigger vesting; no compensation committee interlocks .
  • Overall: May’s human capital and finance expertise, independence, and active committee leadership are positive signals for governance quality and pay-for-performance discipline during Solventum’s early standalone period .